Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
[email protected]+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

News & Announcements

  • 2023
  • 2022
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

Data from Canine Oncology Study Supports Progression to Registration Studies

19/10/2023

Chief Executive Officer Appointment

28/08/2023

Additional Phase 1 data suggest MPL may inhibit MND

22/08/2023

Cohort 3 Pharmacokinetics in MND Patients Completed

09/08/2023

Appendix 4C and Quarterly Update

31/07/2023

MND Trial Successfully Completes 3rd Patient Cohort

28/07/2023

Canine Trial Update

13/07/2023

Results show MPL suppresses biomarkers associated with MND

11/07/2023

Louie the Beagle surpasses one year on MPL

06/07/2023

MND Biomarkers and Pharmacodynamics Results

04/07/2023

Results of General Meeting

30/06/2023

Motor Neurone Disease Phase 1/2 Clinical Trial Update

27/06/2023

Commencement of Cohort 3 in Phase 1/2 MND Trial

09/06/2023

PharmAust MND Trial Interim Analysis PK Outcomes

07/06/2023

Managing A Pet Cancer Diagnosis Is Possible With Right Resources And Support

06/06/2023

Notice of General Meeting

26/05/2023

Motor Neurone Disease Clinical Trial Update

22/05/2023

Progress update on Phase 1/2 MND interim analysis

16/05/2023

Independent tests show MPL retains long-term shelf-life

10/05/2023

MPL has anti-cancer effects across multiple cancer types

09/05/2023

PharmAust Raises $2.5m via Placement

03/05/2023

MND Trial Successfully Completes Second Patient Cohort

28/04/2023

Appendix 4C and Quarterly Update

28/04/2023

Canine Trial Update

21/04/2023

Arrival of additional MPL tablets

17/04/2023

PharmAust launches international CEO search

13/04/2023

MND Trial Completes Enrolment of Cohort 2

30/03/2023

Stable Patient in MND trial reaches 6-months on MPL

28/03/2023

Canine Cancer Trial Update

27/03/2023

Free Biotech & Nutrition Investor Webinar

17/03/2023

First Patient of Cohort 2 Dosed in MND Trial 3 market sensitive

20/02/2023

PharmAust canine trial update 18 market sensitive

10/02/2023

Appendix 4C and Quarterly Update

30/01/2023

PharmAust Progresses to Elevated Doses in MND Patients

20/01/2023

Fireside chat with Dr Roger Aston

17/01/2023

MND Trial Successfully Completes First Patient Cohort

06/01/2023

Fireside chat with Dr Kim

23/12/2022

PharmAust Canine Trial Update

20/12/2022

PharmAust Receives R&D Tax Incentive Refund

12/12/2022

MND Trial Completes Enrolment of First Patient Cohort

02/12/2022

PhamAust Webinar

17/11/2022

PhamAust AGM 2022

11/11/2022

PharmAust doses first patient with MPL in motor neurone disease trial

03/10/2022

PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease

03/10/2022

PharmAust (ASX:PAA) doses first patient in MND trial

03/10/2022

First Patient Dosed in MND Phase 1/2 Trial

03/10/2022

Notice of Annual General Meeting 2022

30/09/2022

PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin

18/08/2022

Update on PharmAust Canine Cancer Trials

17/08/2022

PharmAust’s MPL trials show doubled life expectancy for dogs with cancer

17/08/2022

PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials

17/08/2022

PharmAust opens door to billion-dollar markets, following MPL trial successes

01/08/2022

Broker JP Equity says PharmAust has multiple avenues to $US 1 billion+ success

27/07/2022

JP Equity Research Report

22/07/2022

Appendix 4C and Quarterly Update

21/07/2022

PharmAust subsidiary Epichem lands pilot deal with Shell Australia to convert waste plastic to products

13/07/2022

July 1, Top 20 Shareholders

01/07/2022

Science Week Conference Presentation

24/06/2022

PharmAust and FightMND band together to fight against Motor Neurone Disease

10/06/2022

June 1, Top 20 Shareholders

01/06/2022

May 30, Fiona Milner appointed Epichem General Manager

30/05/2022

May 27, Resignation of Dr Richard Mollard

27/05/2022

May 24, PharmAust Clinical Trials Update

24/05/2022

May 17, PharmAust receives $210k prepayment of forecast R&D rebate

17/05/2022

May 16, MPL tablets arrive in Melbourne for MND Clinical Trial

16/05/2022

May 11, PharmAust Expands Canine Trial to the US

11/05/2022

May 1, Top 20 Shareholders

01/05/2022

April 29, Appendix 4C and Quarterly Update

29/04/2022

April 19, PharmAust Receives $708k R&D Tax Rebate

19/04/2022

April 1, Top 20 Shareholders

01/04/2022

March 15, PharmAust Manufactured MPL Shipped to the USA for Tableting

15/03/2022

March 1, Top 20 Shareholders

01/03/2022

February 21, Ergomed to Assist Covid Trial Commencement

22/02/2022

February 18, Appendix 4D and Half Year Update

18/02/2022

February 3, Resignation of Epichem CEO

03/02/2022

February 2, Monepantel Tablets for Human Clinical Trials

02/02/2022

February 1, Top 20 Shareholders

01/02/2022

January 31, Appendix 4C and Quarterly Update

31/01/2022

January 1, Top 20 Shareholders

01/01/2022

Fireside chat with Dr Kim

23/12/2022

PharmAust Canine Trial Update

20/12/2022

PharmAust Receives R&D Tax Incentive Refund

12/12/2022

MND Trial Completes Enrolment of First Patient Cohort

02/12/2022

PhamAust Webinar

17/11/2022

PhamAust AGM 2022

11/11/2022

PharmAust doses first patient with MPL in motor neurone disease trial

03/10/2022

PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease

03/10/2022

PharmAust (ASX:PAA) doses first patient in MND trial

03/10/2022

First Patient Dosed in MND Phase 1/2 Trial

03/10/2022

Notice of Annual General Meeting 2022

30/09/2022

PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin

18/08/2022

Update on PharmAust Canine Cancer Trials

17/08/2022

PharmAust’s MPL trials show doubled life expectancy for dogs with cancer

17/08/2022

PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials

17/08/2022

PharmAust opens door to billion-dollar markets, following MPL trial successes

01/08/2022

Broker JP Equity says PharmAust has multiple avenues to $US 1 billion+ success

27/07/2022

JP Equity Research Report

22/07/2022

Appendix 4C and Quarterly Update

21/07/2022

PharmAust subsidiary Epichem lands pilot deal with Shell Australia to convert waste plastic to products

13/07/2022

July 1, Top 20 Shareholders

01/07/2022

Science Week Conference Presentation

24/06/2022

PharmAust and FightMND band together to fight against Motor Neurone Disease

10/06/2022

June 1, Top 20 Shareholders

01/06/2022

May 30, Fiona Milner appointed Epichem General Manager

30/05/2022

May 27, Resignation of Dr Richard Mollard

27/05/2022

May 24, PharmAust Clinical Trials Update

24/05/2022

May 17, PharmAust receives $210k prepayment of forecast R&D rebate

17/05/2022

May 16, MPL tablets arrive in Melbourne for MND Clinical Trial

16/05/2022

May 11, PharmAust Expands Canine Trial to the US

11/05/2022

May 1, Top 20 Shareholders

01/05/2022

April 29, Appendix 4C and Quarterly Update

29/04/2022

April 19, PharmAust Receives $708k R&D Tax Rebate

19/04/2022

April 1, Top 20 Shareholders

01/04/2022

March 15, PharmAust Manufactured MPL Shipped to the USA for Tableting

15/03/2022

March 1, Top 20 Shareholders

01/03/2022

February 21, Ergomed to Assist Covid Trial Commencement

22/02/2022

February 18, Appendix 4D and Half Year Update

18/02/2022

February 3, Resignation of Epichem CEO

03/02/2022

February 2, Monepantel Tablets for Human Clinical Trials

02/02/2022

February 1, Top 20 Shareholders

01/02/2022

January 31, Appendix 4C and Quarterly Update

31/01/2022

January 1, Top 20 Shareholders

01/01/2022

December 15, Epichem Awarded DNDi Extension

15/12/2021

December 13, Shareholder Update and Strategy

13/12/2021

December 1, Demonstration Batch Small MPL Tablets Completed

01/12/2021

December 1, Top 20 Shareholders

01/12/2021

November 17, FightMND and COVID-19 Trials on Track

17/11/2021

November 15, New Zealand Joins Phase 2B Pet Dog Trial

15/11/2021

November 1, Top 20 Shareholders

01/11/2021

October 21, AGM Presentation

21/10/2021

October 21, MPL Demonstration Batch for Human Trials Complete

21/10/2021

October 18, Canine Trial Update

18/10/2021

October 1, Entitlement Options Issue Prospectus

01/10/2021

October 1, Pro-Rata Non-Renounceable Entitlement Options Offer

01/10/2021

October 1, Top 100 Shareholders

01/10/2021

September 30, Top 20 Shareholders

01/10/2021

Sept 10, PharmAust Broker Briefing Presentation

09/09/2021

August 31, Top 20 Shareholders

01/09/2021

August 31, Epichem Pays Off EFA Loan

31/08/2021

August 18, Appendix 4G

18/08/2021

August 18, Appendix 4E

18/08/2021

August 3, Epichem Completes OHD Technology Build

03/08/2021

July 31, Top 20 Shareholders

01/08/2021

July 30, Virtual Investor Briefing for August 12, 2021

30/07/2021

July 28, Appendix 4C and Quarterly Update

28/07/2021

July 26, PharmAust Update on COVID-19 Work

26/07/2021

July 12, PharmAust and WEHI Investigate Monepantel in HTLV-1 infection

12/07/2021

July 9, PharmAust ANZCVS Science Week Presentation

09/07/2021

July 7, Update on Ongoing MPL GMP Tablet Tablet Stability

07/07/2021

June 30, Top 20 Shareholders

01/07/2021

June 28, Phase IIb Dog Cancer Interim Primary Endpoints Attained

28/06/2021

May 31, Top 20 Shareholders

01/06/2021

May 14, Dr Kim Agnew Appointed PI of MPL Dog Cancer Trial

14/05/2021

April 30, Top 20 Shareholders

01/05/2021

April 29, Appendix 4C and Quarterly Update

29/04/2021

April 27, Monepantel Phase IIb Dog Lymphoma Interim Plasma Data

27/04/2021

April 8, PharmAust Receives $750k R&D Tax Incentive Refund

08/04/2021

April 7, LUMC: Monepantel Testing Indicates Anti-Covid19 Activity

07/04/2021

March 31, Top 20 Shareholders

01/04/2021

March 31, Monepantel Phase IIb Dog Lymphoma Trial Update

31/03/2021

March 23, Epichem Waste to Fuel Licensing Agreement with Thermaquatica

23/03/2021

February 28, Top 20 Shareholders

01/03/2021

February 26, Appendix 4D & Half Year Report

26/02/2021

February 15, Canine Monepantel Phase IIb Lymphoma Trial Update

14/02/2021

February 10, LUMC Covid-19 Research Update

10/02/2021

January 31, Top 20 Shareholders

01/02/2021

January 27, Appendix 4C and Quarterly Update

27/01/2021

January 22, Epichem Awarded $200k e-Waste Grant

22/01/2021

January 9, PAA LUMC COVID-19 Research Update

08/01/2021

December 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust04/01/2021

201231_Top_Holders_Report (91)

Read more

December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials

News & Announcements 2020By PharmAust23/12/2020

201223_PAA_Syngene_FightMND_Manufacture

Read more

December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial

News & Announcements 2020By PharmAust22/12/2020

201222_PhaseIIbcaninetrial

Read more

December 21, Epichem Awarded DNDi Extension

News & Announcements 2020By PharmAust21/12/2020

201221_EpichemDNDi

Read more

December 4, Issued Capital

News & Announcements 2020By PharmAust04/12/2020

201204_IssuedCapital

Read more

November 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust01/12/2020

201130_Top_Holders_Report

Read more

November 5, AGM Results

News & Announcements 2020By PharmAust05/11/2020

201105_AnnualGeneralMeeting

Read more

October 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust02/11/2020

201031_Top_Holders_Report (87)

Read more

2020 Annual General Meeting Notice

News & Announcements 2020By PharmAust02/10/2020

201002_2020_Annual General Meeting

Read more

September 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust01/10/2020

Top_Holders_Report (84)

Read more

ONJCRI Monepantel Signalling Pathway Update

News & Announcements 2020By PharmAust29/09/2020

200929_PAA_ONJCRI Update

Read more

LUMC COVID-19 Clarification Statement

News & Announcements 2020By PharmAust28/09/2020

200928_Clarification Statement on LUMC and COVID-19 work

Read more

LUMC and PAA Agreement for COVID-19 Work

News & Announcements 2020By PharmAust24/09/2020

200924_LUMC-PAA-Agreement

Read more

200921_PharmAust Awarded FightMND Grant for Phase I Trial

News & Announcements 2020By PharmAust21/09/2020

200921_PAA_FightMND

Read more

14 September, Shareholder Update

News & Announcements 2020By PharmAust14/09/2020

200914_Shareholder Update

Read more

Elanco not to Exercise Agreed Option

News & Announcements 2020By PharmAust09/09/2020

200909_Elanco not to Exercise Agreed Option

Read more

Monepantel Anti-Covid-19 Activity Confirmed

News & Announcements 2020By PharmAust09/09/2020

200909_Monepantel Anti-Covid-19 Activity Confirmed

Read more

August 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust01/09/2020

200831_Top_20_Holders

Read more

Epichem waste-to-fuels technology partnership

News & Announcements 2020By PharmAust01/09/2020

200901_Epichem waste to fuels technology partnership

Read more

Appendix 4E & Preliminary Final Report

News & Announcements 2020By PharmAust31/08/2020

200831_Appendix 4E & Preliminary Final Report

Read more

Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells

News & Announcements 2020By PharmAust25/08/2020

200825_Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells

Read more

July 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust01/08/2020

200731_top20shareholders

Read more

28 July Appendix 4C and Quarterly Update

News & Announcements 2020By PharmAust28/07/2020

200728_Appendix4CandQuarterlyUpdate

Read more

13 July, Final Report delivered under Option Agreement

News & Announcements 2020By PharmAust13/07/2020

200713_Final Report Option Agreement

Read more

June 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust01/07/2020

200701_topShareholders

Read more

JP Equity Partners – Broker Analyst Report – July 2020

News & Announcements 2020, Research Notes 2020By PharmAust30/06/2020

PAA Research Report – June 2020

Read more

24 June, Shareholder Update

News & Announcements 2020By PharmAust24/06/2020

200624_ShareholderUpdate

Read more

18 June, Confirmation of Covid-19 Monepantel Results

News & Announcements 2020By PharmAust18/06/2020

18 June Confirmation of Covid-19 Monepantel Results

Read more

18 June, Reinstatement of Official Quotation

News & Announcements 2020By PharmAust18/06/2020

18 June, Reinstatement of Official Quotation

Read more

15 June, Voluntary Suspension

News & Announcements 2020By PharmAust15/06/2020

2200615_Voluntary Suspension

Read more

4 June, Preliminary Monepantel SARS-CoV-2 Data

News & Announcements 2020By PharmAust04/06/2020

200604_Preliminary Monepantel SARS-CoV-2 Data

Read more

May 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust01/06/2020

200602_Top_Holders_Report

Read more

12 May, Phase II Trial – Successful Anti-Cancer Outcome

News & Announcements 2020By PharmAust12/05/2020

200512_Phase II Trial Update – Successful Outcome

Read more

April 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust30/04/2020

200501_top20shareholders

Read more

30 April, Appendix 3G Notification of Issue, Conversion or Payment of Equity + Securities

Financial Reports 2020, News & Announcements 2020By PharmAust30/04/2020

200430_Performance rights

Read more

20 April, Appendix 4C and Quarterly Update

Financial Reports 2020, News & Announcements 2020By PharmAust20/04/2020

200420_Appendix 4C and Quarterly Update

Read more

17 April, PharmAust and WEHI evaluate monepantel for COVID-19 in vitro

News & Announcements 2020By PharmAust17/04/2020

200417_Monepantel in SARS-CoV-2

Read more

31 March, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust31/03/2020

200401_Top_Holders

Read more

31 March, Expiry of Options

Financial Reports 2020, News & Announcements 2020By PharmAust31/03/2020

200313_Expiry of Options

Read more

31 March, Phase II Trial Update

News & Announcements 2020By PharmAust31/03/2020

200313_Phase II Dog Trial Update

Read more

3 March, Brisbane Animal Referral Hospital Joins PharmAust Phase II Dog Cancer Trial

News & Announcements 2020By PharmAust03/03/2020

200403_Expansion of Sites

Read more

29 February, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy PharmAust29/02/2020

200229_Top_Holders_Movements_Report

Read more

28 Feb, Appendix 4D & Half Year Report

Financial Reports 2020, News & Announcements 2020By PharmAust28/02/2020

200228_Appendix 4D & Half Year Report

Read more

31 January 2020, Top 20 Shareholders

News & Announcements 2020By PharmAust31/01/2020

200203_Top_Holders_Report

Read more

28 January, Appendix 4C and Quarterly Update

Financial Reports 2020, News & Announcements 2020By PharmAust28/01/2020

200128_Appendix 4C and Quarterly Update

Read more

$700K R&D Tax Incentive Refund.

News & Announcements 2020By PharmAust14/01/2020

200114_$700K R&D Tax Incentive Refund

Read more

Epichem Awarded DNDi Contract Extension

News & Announcements 2020By PharmAust08/01/2020

200108_Epichem Awarded DNDi Contract Extension

Read more

UNITY Announces End to Epichem Contract

News & Announcements 2020By PharmAust07/01/2020

200107_UNITY Announces End to Epichem Contract

Read more

31 December, Top 20 Shareholders

News & Announcements 2019By PharmAust31/12/2019

191231_Top Holders 31 December 2019

Read more

Expanded Site Recruitment for Monepantel Phase II Trial in Pet Dogs with Cancer

News & Announcements 2019By PharmAust11/12/2019

191211_expanded site recruitment

Read more

29 November, Top 20 Shareholders

News & Announcements 2019, Top 20 ShareholdersBy PharmAust02/12/2019

191130_Top_Holders_Report

Read more

Pitt Street Research Life Science Conference: Investor Presentation

Investor Presentations 2019, News & Announcements 2019By PharmAust28/11/2019

191128_Investor Presentation

Read more

Appendix 3B, Exercise of Options

Financial Reports 2019, News & Announcements 2019By PharmAust19/11/2019

191121_Exercise of Options

Read more

Appendix 3B – Exercise of Options

Financial Reports 2019, News & Announcements 2019By PharmAust08/11/2019

191108_Appendix 3B – Exercise of Options

Read more

Progress in Recruitment for Phase II Trial in Dogs

News & Announcements 2019By PharmAust04/11/2019

191104_Progress in Recruitment for Phase II Trial in Dogs

Read more

Appendix 4C and Quarterly Update

Financial Reports 2019, News & Announcements 2019By PharmAust01/11/2019

191101_Appendix 4C and Quarterly Update

Read more

31 October, Top 20 Shareholders

News & Announcements 2019By PharmAust01/11/2019

31 October_Top 20 Shareholders

Read more

Epichem New CEO and Board Additions

News & Announcements 2019By PharmAust14/10/2019

191014_Epichem New CEO and Board Additions

Read more

Appendix 3B & s708 Notice

Financial Reports 2019, News & Announcements 2019By PharmAust10/10/2019

191010_Appendix 3B & s708 Notice

Read more

PharmAust Receives R&D Tax Rebate Pre-Approval

News & Announcements 2019By PharmAust07/10/2019

191007_PharmAust Receives R&D Tax Rebate Preapproval

Read more

Epichem Wins Export Award

News & Announcements 2019By PharmAust04/10/2019

191004_Epichem Wins Export Award

Read more

PharmAust Raises $2.4 Million in Placement

News & Announcements 2019By PharmAust03/10/2019

191003_PharmAust Raises $2.4million

Read more

October 1, Trading Halt

News & Announcements 2019By PharmAust30/09/2019

191001_Trading Halt

Read more

30 September 2019, Top 20 Shareholders

News & Announcements 2019By PharmAust30/09/2019

191001_Top Holders September 2019

Read more

26 September, Exercise of Options

Financial Reports 2019, News & Announcements 2019By PharmAust26/09/2019

190926_Exercise of Options

Read more

24 September, Notice of Annual General Meeting/ Proxy Form

News & Announcements 2019By PharmAust24/09/2019

190924_Notice of Annual General Meeting:Proxy Form

Read more

19 September: Appendix 4G & Corporate Governance Statement

Financial Reports 2019, News & Announcements 2019By PharmAust23/09/2019

190919_Appendix 4G & Corporate Governance Statement

Read more

19 September: Annual_Report

Financial Reports 2019, News & Announcements 2019By PharmAust19/09/2019

190919_Annual_Report

Read more

17 September: Appendix 3B – Exercise of Options

Financial Reports 2019, News & Announcements 2019By PharmAust17/09/2019

190917_Appendix 3B Exercise of Options

Read more

Agreement with U-Vet for Phase II Trial in Pet Dogs with Cancer Finalised

News & Announcements 2019By PharmAust10/09/2019

190910_UniMelb_U-Vet Agreement

Read more

Investor Roadshow Presentation September 2019

Investor Presentations 2019, News & Announcements 2019By PharmAust09/09/2019

190909_Investor Roadshow Presentation September 2019

Read more

Phase II Dog Cancer Trial Commences

News & Announcements 2019By PharmAust09/09/2019

190909_Phase II Dog Cancer Trial Commences

Read more

30 August 2019 Top 20 Shareholders

News & Announcements 2019, Top 20 ShareholdersBy PharmAust02/09/2019

Top Holders August 2019

Read more

Appendix 4E Preliminary Final Report

Financial Reports 2019, News & Announcements 2019By PharmAust30/08/2019

190830_Preliminary Final Report

Read more

Appendix 3B and s708 Notice

Financial Reports 2019, News & Announcements 2019By PharmAust28/08/2019

190828_Appendix 3B & s708 notice

Read more

Arrival of GMP Tablets for Phase II Dog Trials

News & Announcements 2019By PharmAust26/08/2019

190826_GMP Tablets Arrive_447v3rv314vgd9

Read more

Change of Director’s Interest Notice

News & Announcements 2019By PharmAust16/08/2019

190816_Change of Director's Interest Notice 447k299n9rnrts

Read more

31 July 2019 Top 20 Shareholders

News & Announcements 2019, Top 20 ShareholdersBy PharmAust31/07/2019

190731_Top_Holders_Report (33)

Read more

Appendix 4C and Quarterly Update

Financial Reports 2019, News & Announcements 2019By PharmAust30/07/2019

4471277nx3858c

Read more

Appendix 3B & s708 Notice

Financial Reports 2019, News & Announcements 2019By PharmAust26/07/2019

190729_Unlisted Options Issuance

Read more

July 25 Investor Presentation

Investor Presentations 2019, News & Announcements 2019By PharmAust26/07/2019

190725_PAA PRESENTATION 25 JULY 2019

Read more

Response to ASX Price and Volume Query

News & Announcements 2019By PharmAust23/07/2019

Response to ASX Price and Volume Query

Read more

23 July 2019, Change in Substantial Holding

Financial Reports 2019, News & Announcements 2019By PharmAust23/07/2019

Change in Substantial Holding

Read more

Ethics Approval to Use Monepantel Tablet in Dogs with Cancer

News & Announcements 2019By PharmAust14/07/2019

190715_Dog Phase II

Read more

Top 20 Shareholders, 5 July 2019

News & Announcements 2019, Top 20 ShareholdersBy PharmAust05/07/2019

190705_Top20Shareholders

Read more

PharmAust Featured in BioWorld

News & Announcements 2019By PharmAust03/07/2019

190703_BWT06112019

Read more

Epichem’s Completes New Laboratory Financing on Time

News & Announcements 2019By PharmAust02/07/2019

190702_Epichem Loan_Repayment

Read more

GMP Manufacture for Phase 2 Canine Trials

News & Announcements 2019By PharmAust04/06/2019

190604_GMP Manufacture

Read more

Top 20 Shareholders, 31 May 2019

News & Announcements 2019, Top 20 ShareholdersBy PharmAust03/06/2019

Top_Holders_Report (22)

Read more

25 kg of GMP Monepantel from Elanco

News & Announcements 2019By PharmAust08/05/2019

190508_GMP_25kg

Read more

30 April, Top 20 Shareholders

News & Announcements 2019, Top 20 ShareholdersBy PharmAust06/05/2019

Top_Holders_Report (2)

Read more

PharmAust Limited Monepantel Tablets Demonstrate High Safety During Phase I Trial

News & Announcements 2019By PharmAust03/05/2019
Read more

Appendix 4C and Quarterly Update

Financial Reports 2019, News & Announcements 2019By PharmAust01/05/2019

444r10lc14lvz2

Read more

30 April, Top 20 Shareholders

News & Announcements 2019By PharmAust30/04/2019

Top_Holders_Report (2)

Read more

2017 to 2018 R&D Tax Rebate: $672k

News & Announcements 2019By PharmAust30/04/2019

2017:2018 $672k R&D Tax Rebate

Read more

Appendix 3B

Financial Reports 2019, News & Announcements 2019By PharmAust24/04/2019

Appendix 3B

Read more

11 April: Shortfall Placement Oversubscribed

News & Announcements 2019By PharmAust11/04/2019

190411_Shortfall Placement Oversubscribed

Read more

Change of Directors’ Interest: Appendix 3Y

News & Announcements 2019By PharmAust28/03/2019

190329_Directors Interest

Read more

Phase I Monepantel Tablets Demonstrate High Safety

News & Announcements 2019By PharmAust28/03/2019

190326_Scaled tablet single dose safety performance (clean)

Read more

Top 20 Shareholders, March 2019

News & Announcements 2019, Top 20 ShareholdersBy PharmAust27/03/2019

PAA Top 20 as at 260319

Read more

PharmAust Raises $1.3m in Rights Issue

News & Announcements 2019By PharmAust22/03/2019

190322_Rights Issue Raises 1.3m

Read more

Monepantel Tablets Positive Performance in Phase I

News & Announcements 2019By PharmAust14/03/2019

190314_PhaseI part A

Read more

Intellectual Property Update

News & Announcements 2019By PharmAust05/03/2019

190305_Intellectual Property Update

Read more

Appendix 4D and Financial Report

Financial Reports 2019, News & Announcements 2019By PharmAust01/03/2019

190301_Appendix-4D-and-Financial-Report

Read more

Top 20 Shareholders, March 1

News & Announcements 2019, Top 20 ShareholdersBy PharmAust01/03/2019

190301_Top_20 Shareholders March 1

Read more

Offer Document – Rights Issue

News & Announcements 2019By PharmAust25/02/2019

190227_Offer_Document

Read more

Phase I in Dogs Commences using New Monepantel Tablets

News & Announcements 2019By PharmAust19/02/2019

190220_Phase I starts

Read more

Letter to Shareholder

News & Announcements 2019By PharmAust19/02/2019

190219_Letter to Shareholder

Read more

Letter to Optionholder

News & Announcements 2019By PharmAust18/02/2019

190218_Letter to Optionholder

Read more

Section 708A

Financial Reports 2019, News & Announcements 2019By PharmAust18/02/2019

190218_Section 708A

Read more

Non-renounceable Rights Offer

News & Announcements 2019By PharmAust18/02/2019

190218_Non-renounceable rights offer

Read more

DNDi Contract Extension

News & Announcements 2019By PharmAust18/02/2019

190218_DNDi_Extension

Read more

Appendix 3B

Financial Reports 2019, News & Announcements 2019By PharmAust18/02/2019

190218_Appendix 3B

Read more

Appendix 3B Amendment

Financial Reports 2019, News & Announcements 2019By PharmAust14/02/2019

190214_Appendix 3B Amendment

Read more

Monepantel Tablet Taste Masking Test Successfully Completed

News & Announcements 2019By PharmAust10/02/2019

190211_taste_test

Read more

Section 708A

Financial Reports 2019, News & Announcements 2019By PharmAust07/02/2019

190207_Section 708A

Read more

Appendix 3B

Financial Reports 2019, News & Announcements 2019By PharmAust07/02/2019

190207_Appendix 3B

Read more

Top 20 Shareholders January 2019

News & Announcements 2019, Top 20 ShareholdersBy PharmAust06/02/2019

Top_Holder_-_Detail_-_Single_Date january

Read more

Tablet Scaled Manufacture for Phase I Trials

News & Announcements 2019By PharmAust06/02/2019

190207_ScaledTablets

Read more

Phase I Trial Design

News & Announcements 2019By PharmAust06/02/2019

190207_PhaseIDesign

Read more

December 2018 Appendix 4C Quarterly Report and Company Update

Financial Reports 2019, News & Announcements 2019By PharmAust31/01/2019

190131_4C

Read more

PharmAust and Elanco Data Sharing Agreement for Dog Trials

News & Announcements 2019By PharmAust28/01/2019

190129_Elanco_tox_package

Read more

Monepantel uptake responds to diet and tablet design

News & Announcements 2019By PharmAust21/01/2019

190121_Optimisation of Monepantel Uptake

Read more

Monepantel Metabolite Shows Anticancer Activity

News & Announcements 2019By PharmAust15/01/2019

190115_metabolite

Read more

Top 20 Shareholders December 2022

01/01/2023

Top 20 Shareholders November 2022

01/12/2022

Top 20 Shareholders 30th December 2018

07/01/2019

Top 20 Shareholders 14 December 2018

17/12/2018

PharmAust Manufacturing Method Maintains Drug Potency

02/12/2018

GMP Tablet Production for Clinical Trials Commences

13/11/2018

2018 AGM Results

09/11/2018

2018 AGM Presentation

09/11/2018

Top 20 Shareholders 31st October 2018

06/11/2018

Drug Reformulation Play With Significant Potential

06/11/2018

September 2018 Appendix 4C Quarterly Report and Company Update

01/11/2018

GMP Method for PharmAust Analogue Pipeline

29/10/2018

PharmAust Progresses Monepantel Tablet Program for Cancer

14/10/2018

Notice of Annual General Meeting: November 9

10/10/2018

October 8, Director’s Interest

08/10/2018

Top 20 Shareholders October 2018

05/10/2018

Mr Neville Bassett AM Appointed to PharmAust Board

02/10/2018

PharmAust 2018 Annual Report

01/10/2018

Corporate Governance

01/10/2018

Top 20 Shareholders September 2018

24/09/2018

Olivia Newton-John Cancer Research Institute Update

10/09/2018

Preliminary Final Statements to the ASX

03/09/2018

Hope on the horizon for chemo alternative

17/08/2018

Top 20 Shareholders August 2018

17/08/2018

Share Holder Update

31/07/2018

Top 20 Shareholders July 2018

13/07/2018

Epichem Accreditation

02/07/2018

Becoming a Substantial Holder

29/06/2018

Director’s Interest Part II

27/06/2018

Director’s Interest Part I

27/06/2018

Director’s Interest

26/06/2018

Top 20 Shareholders June 2018

10/06/2018

Epichem Award

07/06/2018

Reformulation Update

28/05/2018

Chief Executive Officer resigns

21/05/2018

PharmAust Appendix 4C and Shareholders Update (Q3, 2018 FY)

01/05/2018

Top 20 Shareholders April 2018

27/04/2018

PharmAust enters option to license agreement with Elanco for dog cancer treatment

18/04/2018

Trading Halt

16/04/2018

Wayne Best appointed Epichem Chairman and Dr Keenan as CEO

10/04/2018

SECONDARY TRADING NOTICE PURSUANT TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001

20/03/2018

Appendix 3B: New issue announcement, application for quotation of additional securities and agreement

16/03/2018

Appendix 3Y: Change of Director’s Interest Notice

16/03/2018

PharmAust new collaboration with leading cancer research institute on its MPL drug candidate

14/03/2018

Appendix 4D – Half Yearly Report for Dec, 2017

01/03/2018

PharmAust receives $354k R&D Tax Incentive Refund

28/02/2018

Top 20 Shareholders Feb 2018

26/02/2018

Results of General Meeting

26/02/2018

Appendix 4C and Shareholders Update (Q2, 2018 FY)

31/01/2018

Monepantel reformulation successfully increases dose and improves taste

30/01/2018

NOTICE OF GENERAL MEETING AND EXPLANATORY STATEMENT

29/01/2018

Epichem Awarded One Year Contract Extension from DNDi

18/01/2018

International Vet Cancer Specialist Joins PharmAust Veterinary Advisory Board

17/12/2017

Top 20 Shareholders December 2017

15/12/2017

Phase II Dog Lymphoma Trial Confirms Monepantel Clinical Benefit

13/12/2017

PharmAust Raises $1.873m via an Oversubscribed Placement

06/12/2017

Results of AGM 2017

01/12/2017

Trading Halt Request

01/12/2017

AGM Presentation 2017

01/12/2017

PharmAust Identifies New Proprietary Monepantel-related Compounds With Greater Anti-cancer Activity

23/11/2017

PharmAust secures patent in US for new portfolio of anticancer drugs

16/11/2017

Dogs needed to help evaluate a promising new anti-cancer drug

13/11/2017

Epichem Update

01/11/2017

AGM notice

01/11/2017

Monepantel reformulation project continues to progress

17/10/2017

PharmAust secures broad patent in US for non-cancer applications of Monepantel

10/10/2017

Two key appointments to bolster PharmAust veterinary drug programs

03/10/2017

Appendix 4C – Quarterly Report and Company Update for the period ended 30 September 2017

30/09/2017

Reformulation project achieves first milestones and on- track

20/09/2017

PharmAust secures core Europe patent

12/09/2017

PharmAust and Nihon Nohyaku Japan Enter Assignment Agreement of Joint Patents

04/09/2017

Appendix 4G

31/08/2017

Investor Presentation (August)

31/08/2017

Shareholders Update

22/08/2017

Epichem Reports Record $3m Revenues and Expands Laboratory to Accelerate Growth

17/07/2017

Appendix 4E & Annual Report

10/07/2017

Appendix 4C – Quarterly Report & Company Update for the period ended 30 June 2017

30/06/2017

PharmAust engages Canadian-based specialists to reformulate monepantel

27/06/2017

PharmAust secures broad European patent for non-cancer applications

08/06/2017

PharmAust secures core patent in Japan

06/06/2017

PharmAust Shareholders Update and Roadmap

30/05/2017

Phase II dog lymphoma trial preliminary results demonstrate Monepantel clinical benefit

19/05/2017

PharmAust secures broad patent coverage for non-cancer applications

17/05/2017

Investor Presentation (May)

10/05/2017

PharmAust secures core China patent

05/05/2017

Appendix 4C – Quarterly Report & Company Update for the period ended 31 March 2017

13/04/2017

Dr Richard Mollard appointed as Chief Scientific Officer of PharmAust

08/03/2017

PharmAust raises a further $534K

03/03/2017

Dr Richard Hopkins Appointed as CEO of PharmAust

01/03/2017

Appendix 4C – Quarterly Report & Company Update for the period ended 31 December 2016

31/01/2017

PharmAust receives $406K R&D rebate from ATO

30/01/2017

Appendix 4D Half-Year Report for the period ended 31 December 2016

31/12/2016

Appendix 4D Half-Year Report for the period ended 31 December 2016

31/12/2016

Appendix 4D & Half Yearly Report and Accounts

31/12/2016

PharmAust raises a further 1.56m

30/12/2016

Completion of rights issue and notice shortfall

08/12/2016

Rights issue – Extension of closing date

05/12/2016

No extension of closing date in rights issue

05/12/2016

Phase II Strategy Update

21/11/2016

Results of annual general meetings

11/11/2016

Appendix 3B

11/11/2016

Notice of annual general meeting and explanatory statement

11/11/2016

PharmAust Limited (ASX – PAA) Secondary trading notice

10/11/2016

PharmAust AGM presentation

10/11/2016

Non renounceable rights offer

07/11/2016

Prospectus

01/11/2016

Appendix 4C – Quarterly Report & Company Update for the period ended 30 September 2016

31/10/2016

Second canine receives treatment in trial

14/10/2016

Phase II canine trial begins at the university of Cambridge

19/09/2016

Epichem achieves ISO 90001-2015 certification

16/09/2016

MPL capsules shipped to centres in NSW & Qld for Phase II

13/09/2016

PharmAust Investor Presentation – June 2016

10/08/2016

Further Canine Trials to be Initiated in Australia

10/08/2016

IP exchange with UNSW consolidates MPL patent position

03/08/2016

Reformulated MPL capsules completed, Phase II to commence

11/07/2016

Appendix 4E Annual Report & Full Year Statutory Accounts 2016

01/07/2016

Appendix 4G & Corporate Governance Statement

30/06/2016

University of Cambridge to begin Phase II Trial

27/06/2016

Epichem Successful in AusTrade Grant

16/06/2016

Epichem Successful in AusTrade Grant

16/06/2016

Mandate signed to raise capital in USA & list on NASDAQ

03/05/2016

Appendix 4C Quarterly Report & Brief Company Update

29/04/2016

RedChip issues research on PharmAust

11/03/2016

Strategy for Phase II Clinical Trial of Monepantel

08/03/2016

PharmAust Featured on The RedChip Money Report on Bloomberg

12/02/2016

PharmAust to Present at RedChip Global Online Microcap Conf

08/02/2016

Notice of Allowance received from USA Patent OffIce

05/02/2016

PharmAust Receives $546K R&D Rebate from ATO

01/02/2016

Appendix 4C – Quarterly Report & Company Update

29/01/2016

Juniper Pharma Services to reformulate MPL for Phase II

11/01/2016

PharmAust Featured on RedChip Money Report on Bloomberg

04/01/2016

Epichem Successful in AusTrade Grant

16/06/2015

PharmAust Broker Roadshow Presentation – April 2015

17/04/2017

USA Roadshow Presentation – January 2016

15/01/2016

Epichem Awarded Two Year Contract Extension from DNDi

21/12/2015

Appendix 3B & 708 Notice

04/12/2015

Change of Director’s Interest Notice

03/12/2015

GenScript Further Pre-Clinical Validation for Phase II Trial

26/11/2015

RedChip appointed to begin Global Investor Relations Program

24/11/2015

Change of Director’s Interest Notice

13/11/2015

Appendix 3B

05/11/2015

Appendix 4C Quarterly Report & Company Update

30/10/2015

Consolidation of Capital

27/10/2015

Results of Annual General Meetings 2015

27/10/2015

PharmAust AGM Presentation 2015

27/10/2015

Change of Director’s Interest Notice

22/10/2015

Notice of Annual General Meeting

22/10/2015

Clinical Trial Report Following Phase I Trial

21/10/2015

Change of Registered Office & Principal Place of Business

19/10/2015

Epichem’s New Laboratory Completed

29/09/2015

Consolidation_Split – PAA

22/09/2015

Appendix 3B & 708 Notice

04/09/2015

PharmAust Annual Report 2015

28/08/2015

Final Director’s Interest Notice

27/08/2015

Professor Morris plans to retire from PharmAust board

25/08/2015

Change of Director’s Interest Notice

11/08/2015

Clarification on Expiry of Listed Options

03/08/2015

Letter to Optionholders

31/07/2015

Phase I Trial at RAH Meets Safety & Cancer Marker End Points

23/07/2015

Trading Halt

22/07/2015

First Two Canines Complete Combination Therapy With PPL-1

17/07/2015

Appendix 4G & Corporate Governance Statement

30/06/2015

Appendix 4E & Full Year Statutory Accounts

30/06/2015

Appendix 4C – Quarterly Report & Company Update

30/06/2015

PharmAust Receives ATO Research & Development Rebate

24/06/2015

PharmAust Initiates Combination Therapy Evaluations in Dogs

17/06/2015

Change of registry address

12/06/2015

Results of Meeting

26/05/2015

Notice of General Meeting_Proxy Form

26/05/2015

EGM Shareholder Presentation

26/05/2015

Second Dog Shows Suppression of Cancer Marker at Days 3 & 7

19/05/2015

Reduction of further Cancer Marker confirmed in Human Trial

14/05/2015

First Dog Shows Suppression of Cancer Marker

01/05/2015

Approval of Dose Escalation of PPL-1 in Human Trial

15/04/2015

Modification of Clinical Trial in Dogs

13/04/2015

PharmAust Broker Roadshow Presentation – April 2015

10/04/2015

Lyell McEwin Hospital approved to join PharmAust trial

08/04/2015

Appendix 4C Quarterly Report & Company Update

31/03/2015

Joint Patent with Japanese Corporation now published

30/03/2015

Final Patient in Cohort Demonstrates Tumour Marker Reduction

24/03/2015

Appendix 3B and s708 Notice

20/03/2015

Completion of Lowest Dose Cohort in Human Cancer Trial

17/03/2015

PharmAust completes $3.14m Share Placement oversubscribed

16/03/2015

PharmAust Shareholder Presentation – March 2015

15/03/2015

Trading Halt

12/03/2015

American Assoc for Cancer accepts Late-Breaking Abstract

06/03/2015

Human Trial Prelim Results Shows Reduction in Tumour Markers

09/02/2015

Clarification to Quarterly Report & Company Update

03/02/2015

Appendix 4C – Quarterly Report & Company Update

30/01/2015

Shareholder Update – Human & Canine Trials

25/01/2015

Appendix 4D and Half Yearly Report & Accounts

31/12/2014

Change of Director’s Interest Notice

26/11/2014

Change of Director’s Interest Notice

24/11/2014

Change of Director’s Interest Notice

24/11/2014
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
24 Jun

📸 Highlights from the MND Australia Global Day Event at Parliament House!

We teamed up with FightMND to raise awareness and fight for a future free of Motor Neurone Disease. 💙

#MNDAustralia #FightMND #MNDGlobalDay

Reply on Twitter 1805134834358210569 Retweet on Twitter 1805134834358210569 2 Like on Twitter 1805134834358210569 12 Twitter 1805134834358210569
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
21 Jun

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
#ASX @PharmAust

Reply on Twitter 1803984607676654065 Retweet on Twitter 1803984607676654065 1 Like on Twitter 1803984607676654065 3 Twitter 1803984607676654065
pharmaust PharmAust @pharmaust ·
21 Jun

Exciting news for our investors! 🎉 Check out the details of our latest capital raise here: https://investorhub.pharmaust.com/investment-offer/32. Thank you for your continued support! 🌟 #PharmAust

Reply on Twitter 1804030728956711230 Retweet on Twitter 1804030728956711230 2 Like on Twitter 1804030728956711230 7 Twitter 1804030728956711230
Load More

Copyright © 2024 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top